Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome
Phase 3
Completed
- Conditions
- Marfan Syndrome
- Registration Number
- NCT00485368
- Lead Sponsor
- Bayside Health
- Brief Summary
The purpose of this research is to assess the effects of a drug called perindopril on the aorta in people known to have Marfan Syndrome. The aorta is the major artery of the body that comes out of the heart and supplies blood to the body. We know that in people with Marfan Syndrome, the aorta is stiff and this stiffness results in its enlargement over many years. This enlargement of the aorta can be very serious. We know from treatment of other heart conditions that drugs of the same type as perindopril reduce stiffness of the arteries. This type of drug has never been tried in people with Marfan Syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
- Age 18-40
- Diagnosis of Marfan Syndrome, on the basis of the Ghent Criteria
Exclusion Criteria
- Age <18, >40
- Women of child-bearing potential not on adequate contraception
- Serum creatinine of >0.11
- A history of intolerance to ACEI
- Patients on angiotensin receptor blockers
- Blood pressure >140/90mmHg
- History of previous aortic surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method aortic root diameter 24 weeks
- Secondary Outcome Measures
Name Time Method arterial stiffness 24 weeks